Article Text

Download PDFPDF

2022-RA-566-ESGO Cost-effectiveness of cervical cancer screnning strategies among women in Cameroon
Free
  1. Jessica Sormani1,2,
  2. Ania Wisniak1,
  3. Bruno Kenfack3,4,
  4. Alida Moukam Datchoua3,
  5. Pierre Vassilakos5,
  6. Patrick Petignat1 and
  7. Christophe Combescure1
  1. 1Geneva University Hospitals, Geneva, Switzerland
  2. 2School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Geneva, Switzerland
  3. 3District Hospital of Dschang, Dschang, Cameroon
  4. 4Faculty of Medicine and Pharmaceutical Sciences, Dschang, Cameroon
  5. 5Geneva Foundation for Medical Education and Research, Geneva, Switzerland

Abstract

Introduction/Background Sub-Saharan Africa has the highest cervical cancer burden worldwide. Before implementing a cervical cancer screening programme, National authorities and decision-makers need to balance the benefits and costs of context-sensitive solutions. Our aim was to assess the cost-effectiveness of two cervical cancer screening strategies in Cameroon: i) HPV self-testing (Self-HPV), and (ii) Self-HPV and triage with Visual Inspection with Acid acetic (VIA) (Self-HPV/VIA) at frequencies twice to seven times between 30 and 60 years, at 5 or 10-year intervals.

Methodology A lifetime decision-analytic model has been calibrated to Cameroonian women. Costs parameters have been estimated based on real-life screening activities within the 3T-project in Cameroon. Utilities were accounted for in the model. Cost-effectiveness ratios have been assessed for each strategy and screening frequency compared with the absence of strategy.

Results Four combinations appeared to be the most cost-effective: Self-HPV/VIA at 35–45, and at 30–40–50 years, and Self-HPV every 5 and 10 years between 30 and 60 years old. The incremental cost per QALY gained for Self-HPV/VIA strategies was 403USD (393–413) at 35–45 years, and 690USD (671–708) at 30–40–50 years, 1035USD (1005–1057) for Self-HPV at 30–40–50–60 years, and 1592USD (1553–1620) at 30–35–40–45–50–55–60 years. Cervical cancer mortality was mostly lower with Self-HPV strategies.

Whatever the screening frequency, in both strategies, about 50% of costs were related to Self-HPV testing, while for the Self-HPV/VIA strategy, triage accounted for approximately 1% of costs. At equal frequencies, costs of precancerous treatment were higher in Self-HPV than Self-HPV/VIA strategies, due to high overtreatment rate of CIN1 in the absence of triaging. The costs of cancer treatment were comparable in both strategies.

Conclusion Cost-effectiveness depends on the type and frequency of screening. These results may support decision-makers in selecting adequate screening strategies and frequencies according to their willingness to pay per QALY gained.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.